199 related articles for article (PubMed ID: 37550562)
21. Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
Zhong Q; Hu Z; Li Q; Yi T; Li J; Yang H
Gynecol Oncol; 2019 Jan; 152(1):157-165. PubMed ID: 30414739
[TBL] [Abstract][Full Text] [Related]
22. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.
Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK
Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629
[TBL] [Abstract][Full Text] [Related]
23. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
Kim H; Xu H; George E; Hallberg D; Kumar S; Jagannathan V; Medvedev S; Kinose Y; Devins K; Verma P; Ly K; Wang Y; Greenberg RA; Schwartz L; Johnson N; Scharpf RB; Mills GB; Zhang R; Velculescu VE; Brown EJ; Simpkins F
Nat Commun; 2020 Jul; 11(1):3726. PubMed ID: 32709856
[TBL] [Abstract][Full Text] [Related]
24. Breaking the Iron Homeostasis: A "Trojan Horse" Self-Assembled Nanodrug Sensitizes Homologous Recombination Proficient Ovarian Cancer Cells to PARP Inhibition.
Li Y; Cen Y; Fang Y; Tang S; Li S; Ren Y; Zhang H; Lu W; Xu J
ACS Nano; 2022 Aug; 16(8):12786-12800. PubMed ID: 35920396
[TBL] [Abstract][Full Text] [Related]
25. SN-38 Sensitizes BRCA-Proficient Ovarian Cancers to PARP Inhibitors through Inhibiting Homologous Recombination Repair.
Lin S; Tian J; He Q; Yang M; Chen Z; Belogurov AA; Li X; Zhang F; Liu Y; Chen G
Dis Markers; 2022; 2022():7243146. PubMed ID: 36267463
[TBL] [Abstract][Full Text] [Related]
26. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer.
Ostapoff KT; Awasthi N; Cenik BK; Hinz S; Dredge K; Schwarz RE; Brekken RA
Mol Cancer Ther; 2013 Jul; 12(7):1190-201. PubMed ID: 23696215
[TBL] [Abstract][Full Text] [Related]
27. PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model.
Hammond E; Brandt R; Dredge K
PLoS One; 2012; 7(12):e52175. PubMed ID: 23300607
[TBL] [Abstract][Full Text] [Related]
28. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
29. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
30. The Heparan Sulfate Mimetic PG545 Modulates T Cell Responses and Prevents Delayed-Type Hypersensitivity.
Koliesnik IO; Kuipers HF; Medina CO; Zihsler S; Liu D; Van Belleghem JD; Bollyky PL
Front Immunol; 2020; 11():132. PubMed ID: 32117279
[TBL] [Abstract][Full Text] [Related]
31. Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations.
Yalon M; Tuval-Kochen L; Castel D; Moshe I; Mazal I; Cohen O; Avivi C; Rosenblatt K; Aviel-Ronen S; Schiby G; Yahalom J; Amariglio N; Pfeffer R; Lawrence Y; Toren A; Rechavi G; Paglin S
PLoS One; 2016; 11(5):e0155711. PubMed ID: 27196668
[TBL] [Abstract][Full Text] [Related]
32. PARP Inhibitors in Ovarian Cancer: A Review.
O'Malley DM; Krivak TC; Kabil N; Munley J; Moore KN
Target Oncol; 2023 Jul; 18(4):471-503. PubMed ID: 37268756
[TBL] [Abstract][Full Text] [Related]
33. Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB-Triggered SASP in Cancer-Associated Fibroblasts.
Jin P; Li X; Xia Y; Li H; Li X; Yang ZY; Wang Z; Xu C; Fang T; Zhou D; Xiong X; Wang SY; Xu S; Gao Q
Mol Cancer Ther; 2023 Apr; 22(4):447-458. PubMed ID: 36780236
[TBL] [Abstract][Full Text] [Related]
34. KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer.
Wu Y; Chen S; Shao Y; Su Y; Li Q; Wu J; Zhu J; Wen H; Huang Y; Zheng Z; Chen X; Ju X; Huang S; Wu X; Hu Z
Adv Sci (Weinh); 2023 Nov; 10(31):e2304638. PubMed ID: 37702443
[TBL] [Abstract][Full Text] [Related]
35. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
Ding L; Wang Q; Martincuks A; Kearns MJ; Jiang T; Lin Z; Cheng X; Qian C; Xie S; Kim HJ; Launonen IM; Färkkilä A; Roberts TM; Freeman GJ; Liu JF; Konstantinopoulos PA; Matulonis U; Yu H; Zhao JJ
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609487
[TBL] [Abstract][Full Text] [Related]
36. Depletion of DNA damage binding protein 2 sensitizes triple-negative breast cancer cells to poly ADP-ribose polymerase inhibition by destabilizing Rad51.
Zhao L; Si CS; Yu Y; Lu JW; Zhuang Y
Cancer Sci; 2019 Nov; 110(11):3543-3552. PubMed ID: 31541611
[TBL] [Abstract][Full Text] [Related]
37. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
[TBL] [Abstract][Full Text] [Related]
38. PARP Inhibition Induces Enrichment of DNA Repair-Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells.
Bellio C; DiGloria C; Foster R; James K; Konstantinopoulos PA; Growdon WB; Rueda BR
Mol Cancer Res; 2019 Feb; 17(2):431-445. PubMed ID: 30401718
[TBL] [Abstract][Full Text] [Related]
39. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.
Sakogawa K; Aoki Y; Misumi K; Hamai Y; Emi M; Hihara J; Shi L; Kono K; Horikoshi Y; Sun J; Ikura T; Okada M; Tashiro S
Cancer Sci; 2013 Dec; 104(12):1593-9. PubMed ID: 24033642
[TBL] [Abstract][Full Text] [Related]
40. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]